Recovery / Repair
Research Compound — Animal PK Data Only · No Published Human PK Study
BPC-157 Half-Life: What Rat Data Shows and Humans Do Not Know
BPC-157 is a synthetic 15-amino-acid peptide. A rat pharmacokinetic study reported rapid plasma clearance after subcutaneous administration. Human half-life, bioavailability, efficacy, effect duration, and an appropriate human schedule remain unknown.
Concise citation summary
BPC-157: Halflife Labs records ~15 min plasma (rat) for SC / Oral / IM. Evidence classification: Preclinical, inferred, community, or unresolved source. Source summary: Xu et al., Front Pharmacol 2022, PMC9794587.
Limitation: This value is estimated, inferred, or derived from nonhuman or lower-confidence evidence and cannot be assumed to apply to an individual human. Scientific review is documented on this page; the limited reviewer scope is defined on the About page.
Stable record ID: hlc:bpc-157 · Page revision: 2026-06-11 · Open the primary source
BPC-157 Evidence Update: The Direct Answer
The human half-life of BPC-157 is unknown. The approximately 15-minute figure comes from a rat pharmacokinetic study and cannot be assumed to describe human exposure. No FDA-approved BPC-157 product exists, and FDA has identified BPC-157 among bulk substances that may present significant safety risks in compounding.
What the Rat Study Establishes
The 2022 pharmacokinetic study measured BPC-157 in rats after intravenous and subcutaneous administration and described rapid exposure and tissue distribution in that animal model. It is a useful primary source for preclinical pharmacokinetics. It does not establish human half-life, human bioavailability, a clinically effective dose, a treatment schedule, or long-term human safety.
Question Best-supported answer Evidence limit What is the human half-life? Unknown No suitable published human PK study identified What does ~15 minutes describe? A rat-study plasma estimate after subcutaneous administration Species and study-design limits apply Does short plasma presence prove days of human effects? No Human pharmacodynamic duration is not established Is BPC-157 FDA approved? No approved product identified FDA also flags potential compounding safety risks
Why Clearance and Claimed Effect Duration Must Be Separated
A biological response can outlast plasma exposure in some systems, but that general pharmacology principle does not prove a specific 24- to 72-hour human BPC-157 effect window. Claims about durable repair signaling, systemic outcomes, or an optimal schedule require direct evidence. Where that evidence is absent, the correct answer is unknown.
What a Tracker Can Responsibly Record
A tracker can preserve a research-context event, route, timestamp, unit, source, and notes. It cannot validate a product's identity, safety, efficacy, dose, or human pharmacokinetics. Model outputs based on the rat value must be labeled as nonhuman estimates.
Evidence correction: community protocol amounts and schedules are not human pharmacokinetic evidence and are not presented as recommendations on this page.
Primary Sources and Regulatory Context
Xu P, et al. Pharmacokinetics and tissue distribution of BPC-157 in rats. Open PMC article. FDA. Certain bulk drug substances for use in compounding that may present significant safety risks. Open FDA page.
⚠ No Published Human Pharmacokinetic Data All half-life values for BPC-157 are derived from animal (rat and dog) studies. These values cannot be assumed to apply to humans. No formal human pharmacokinetic study has been published in peer-reviewed literature as of May 2026.
Quick Reference: BPC-157 Pharmacokinetics
Parameter Value Source Plasma Half-Life (SC, rat) ~15 minutes Xu et al. 2022 [1] Plasma Half-Life (IV, animal) ~4–5 minutes (estimated) Animal PK data [1] Time to Peak (Tmax) — SC ~15–30 minutes (animal) Xu et al. 2022 [1] Route(s) of Administration SC injection, IM injection, Oral — Human biological effect duration Unknown No suitable human evidence establishes a duration Full Plasma Clearance (5 half-lives) ~75 minutes (animal estimate) Calculated Human dose or schedule Not established No FDA-approved instructions or suitable human PK basis Data Quality Animal Study — No published human PK data exists as of May 2026 —
Last reviewed: June 11, 2026 · Published: May 2025 · Updated: May 2026
What Is the Half-Life of BPC-157?
BPC-157's plasma half-life of approximately 15 minutes is derived from a 2022 rat pharmacokinetic study by Xu et al. (PMC9794587)[1], which characterized subcutaneous absorption, estimated plasma-remaining curves, and tissue distribution in animal models. This is the primary peer-reviewed pharmacokinetic data set for BPC-157. No equivalent study has been conducted in humans, and no human PK data has been published in peer-reviewed literature as of May 2026.
The peptide's rapid plasma clearance is a direct consequence of its molecular structure: BPC-157 is an unmodified 15-amino-acid sequence with no albumin-binding modifications, no PEGylation, and no half-life extension technology. These structural features make it susceptible to rapid proteolytic degradation by circulating and tissue-bound peptidases, as well as renal filtration given its small molecular weight.
How BPC-157's Half-Life Is Measured — and Why Animal Data Is the Only Available Source
Plasma half-life is measured by tracking compound concentration in blood samples over time following administration. In the Xu et al. 2022 study[1], rats received subcutaneous BPC-157 injections, and serial blood samples were collected to construct a plasma concentration-time curve. The time required for plasma concentration to fall by 50% — the half-life — was approximately 15 minutes for the subcutaneous route.
For intravenous administration in animal models, clearance is estimated to be faster (approximately 4–5 minutes), as the compound enters systemic circulation directly without the absorption phase associated with subcutaneous injection. These estimates are consistent with the compound's structural properties but have not been independently confirmed in prospective human studies.
The Three-Layer Model: Plasma Half-Life ≠ Detection Window ≠ Biological Effect Duration
This is the most clinically and practically important concept in BPC-157 pharmacology, and it is widely misunderstood. BPC-157 has three entirely distinct pharmacological timescales, each measuring something different:
Layer 1 — Plasma Half-Life (~15 minutes, animal data): This measures how quickly the intact BPC-157 molecule disappears from the bloodstream. After approximately 75 minutes (5 half-lives), less than 3% of the original dose remains in plasma. This is a pharmacokinetic measurement of molecular presence, not of biological activity. It tells you when the peptide has left the blood — not when it stops working[1].
Layer 2 — Detection: A universal detection window is not established here. Standard panels and specialized anti-doping methods differ, and athletes should consult the current rules and testing authority.
Layer 3 — Human biological effect duration: Unknown. Preclinical signaling observations do not establish a 24- to 72-hour human effect window.
How Long Does BPC-157 Stay in Your System?
Based on the animal pharmacokinetic data from Xu et al. 2022[1], plasma clearance of BPC-157 following subcutaneous injection follows predictable first-order kinetics with an approximately 15-minute half-life:
Half-Lives Elapsed Time Post-Injection % Remaining in Plasma 1 ~15 minutes 50% 2 ~30 minutes 25% 3 ~45 minutes 12.5% 4 ~60 minutes 6.25% 5 (clinical clearance threshold) ~75 minutes ~3%
Important: This table describes plasma clearance only, derived from animal (rat) data. Biological effects persist far beyond plasma clearance thresholds. These values should not be assumed to apply to humans in the absence of published human pharmacokinetic studies.
Plasma Clearance vs Biological Effect Duration
Plasma clearance and biological effect duration are not the same measurement. BPC-157 reaches clinical plasma clearance (less than 3% of original concentration) within approximately 75 minutes of subcutaneous injection in rat models. However, the downstream signaling cascades activated by BPC-157 — VEGFR2 phosphorylation, Akt-eNOS pathway activation, ERK1/2 signaling, and FAK-paxillin cytoskeletal remodeling — continue to operate for hours to days after the peptide has left circulation[1]. This is the pharmacokinetic/pharmacodynamic disconnect that makes BPC-157 unique among repair peptides and explains why once-daily administration is standard despite the short plasma half-life.
Why the Rat Half-Life Does Not Establish Human Dosing
Why Daily Injections Despite <30 Minute Half-Life?
A short plasma half-life in rats does not establish a human dose, frequency, or biological-effect window. Community protocols are not a substitute for human pharmacokinetic, efficacy, or safety evidence.
This mechanism is fundamentally different from drugs that require continuous receptor occupancy — such as many enzyme inhibitors or receptor antagonists — where plasma concentration directly determines magnitude of effect. BPC-157 operates more like a growth factor: brief engagement with its receptor triggers a prolonged downstream transcriptional and structural response.
Oral vs Subcutaneous BPC-157 — PK Considerations
BPC-157 is occasionally administered orally, particularly in research focused on gastrointestinal conditions including inflammatory bowel disease, gastric ulceration, and gut-brain axis modulation. Oral peptide administration typically raises concerns about enzymatic degradation in the gastrointestinal tract before systemic absorption, which would be expected to substantially reduce bioavailability for most peptides.
BPC-157 appears to have some resistance to gastric acid degradation in animal studies, which is one mechanistic rationale for exploring oral administration — particularly for locally acting effects in the gastrointestinal tract where systemic absorption may not be necessary for efficacy. However, no published human pharmacokinetic study has characterized oral bioavailability for BPC-157, and systemic bioavailability via oral route in humans remains unknown. For effects requiring systemic distribution (tendon repair, systemic angiogenesis), subcutaneous or intramuscular injection is the preferred route in research protocols.
BPC-157 vs Recovery Peptide Comparators
Compound Plasma Half-Life Data Source Data Quality BPC-157 ~15 min (SC, rat) Xu et al. 2022 [1] Animal Study TB-500 Not formally published — Inferred — no published PK study GHK-Cu (topical) Minutes (estimated) Structural analog data Inferred KPV <30 min (estimated) Animal data Animal Study
Pharmacokinetics by Route of Administration
Route Half-Life Bioavailability Tmax Notes Subcutaneous ~15 min (rat) Unknown in humans ~15–30 min (animal) Rat PK route; not an approved human use Intramuscular No published data No published data No published data Human PK unknown Intravenous ~4–5 min (estimated) 100% Minutes Reference route; rapid clearance Oral No published data Potentially low (peptide degradation risk) Unknown Explored in GI repair research; some gastric acid resistance in animals
Detection Window
A universal BPC-157 detection window is unknown. Routine workplace panels and specialized anti-doping assays are different systems. Competitive athletes should consult the current prohibited list and their testing authority rather than relying on a generalized time estimate.
Mechanism — What the Preclinical Evidence Can Support
The rat study supports rapid plasma clearance in that model. Mechanistic publications discuss possible signaling pathways, but those observations do not establish a human clinical effect, effect duration, or treatment schedule.
The correct evidence boundary is simple: animal pharmacokinetics can inform a preclinical model; it cannot be converted into an exact human pharmacokinetic or pharmacodynamic claim.
Track Your BPC-157 Protocol
Preserve a timestamped research-context record while keeping all nonhuman model assumptions explicit. Download on App Store
Comparison guide: Read BPC-157 vs TB-500 for local vs systemic repair, the half-life evidence gap, and regulatory status.
Frequently Asked Questions
What is the half-life of BPC-157?
BPC-157 has a plasma half-life of approximately 15 minutes in rat pharmacokinetic studies following subcutaneous administration, based on Xu et al. (2022, PMC9794587). In intravenous administration, plasma clearance is more rapid — estimated 4–5 minutes in animal models. No published human pharmacokinetic study has characterized BPC-157's half-life in humans. Data quality: Animal Study — these values cannot be assumed to apply to humans.
How long does BPC-157 stay in a human system?
Unknown. The approximately 75-minute five-half-life calculation applies only to a simple model built from a rat-study value. Human elimination and biological-effect duration have not been established by a suitable published human study.
Does the rat half-life establish a human dosing frequency?
No. A rat half-life does not establish a human dose, frequency, efficacy, or safety profile. Community protocol amounts are not clinical instructions.
Can BPC-157 be detected on a drug test?
Testing depends on the panel and method. A universal detection window is not established here. Athletes should consult the current prohibited list and the relevant testing authority.
What is the difference between BPC-157 plasma half-life and effect duration?
They are different concepts, but neither a general pharmacology principle nor preclinical signaling data establishes a specific human BPC-157 effect duration. Human pharmacokinetics and pharmacodynamics remain unknown.
How does BPC-157's half-life compare to TB-500 (thymosin beta-4 fragment)?
BPC-157 has a plasma half-life of approximately 15 minutes in animal studies, based on Xu et al. (2022, PMC9794587). TB-500 (a synthetic fragment of thymosin beta-4) has a longer reported half-life due to its larger molecular weight and different structural properties, though formal published human pharmacokinetic studies are not available for either compound. Both are research compounds used for tissue repair, with no published human pharmacokinetic data for direct comparison.
Does rapid rat plasma clearance prove a lasting human effect?
No. Preclinical signaling hypotheses do not prove human efficacy or a lasting human effect. Direct human evidence would be required.
What should an athlete know about BPC-157 testing?
Rules and analytical capabilities change. Consult the current prohibited list and the responsible anti-doping authority; do not rely on a generalized detection-window claim.
References
[1] Xu P, et al. Pharmacokinetics and Tissue Distribution of BPC-157 in Rats After Subcutaneous Injection. Front Pharmacol. 2022;13:1061882. PMC9794587. PMC9794587 [2] Sikiric P, et al. Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications. Curr Neuropharmacol. 2016;14(8):857–865. PMID 28035768. PMID 28035768
Related Compounds
Log BPC-157 in Halflife
A clearly labeled nonhuman estimate based on recorded timing and the selected model. Free iOS app. Core protocol records stored on-device. Download on App Store